P
Parmanand Malvi
Researcher at University of Alabama at Birmingham
Publications - 24
Citations - 993
Parmanand Malvi is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Melanoma & Cancer. The author has an hindex of 13, co-authored 21 publications receiving 725 citations. Previous affiliations of Parmanand Malvi include National Center for Charitable Statistics & Yale University.
Papers
More filters
Journal ArticleDOI
Oncogene-directed alterations in cancer cell metabolism.
TL;DR: Evidence for oncogene-directed cancer metabolic regulation is presented and the importance of identifying underlying mechanisms that can be targeted for developing precision cancer therapies is discussed.
Journal ArticleDOI
AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1α-mediated mitochondrial biogenesis.
Balkrishna Chaube,Parmanand Malvi,Shivendra V. Singh,Naoshad Mohammad,B Viollet,Manoj Kumar Bhat +5 more
TL;DR: Evidence is provided that AMPK-p38-PGC-1α axis, by regulating energy homeostasis, maintains survival in cancer cells under glucose-limiting conditions and signifies the fundamental role of AMPK in controlling cellular bioenergetics and mitochondrial biogenesis incancer cells.
Journal ArticleDOI
Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.
TL;DR: The major cell-aut autonomous and cell-non-autonomous roles of HS and HSPGs in cancer are described and therapeutic opportunities for targeting deregulated HS biosynthesis and H SPGs as a strategy for cancer treatment are discussed.
Journal ArticleDOI
Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma
Naoshad Mohammad,Parmanand Malvi,Avtar S. Meena,Shivendra V. Singh,Balkrishna Chaube,Garikapati Vannuruswamy,Mahesh J. Kulkarni,Manoj Kumar Bhat +7 more
TL;DR: Treatment with methyl-β-cyclodextrin (MCD), a cholesterol depleting agent, increases the efficacy of tamoxifen in melanoma cells and may provide a unique therapeutic window for improvement in melan cancer treatment.
Journal ArticleDOI
Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex
Naoshad Mohammad,Shivendra V. Singh,Parmanand Malvi,Balkrishna Chaube,Dipti Athavale,Muralidharan Vanuopadath,Sudarslal Sadasivan Nair,Bipin G. Nair,Manoj Kumar Bhat +8 more
TL;DR: Results suggest that MCD enhances the sensitivity to DOX for which wild type p53 is an important determinant, and p53 inhibition by pharmacological inhibitor pifithrin-α or its specific siRNA attenuated p53 function and down-regulated FasR/FasL thereby preventing cell death.